296 related articles for article (PubMed ID: 31341086)
61. Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection.
Akidil E; Albanese M; Buschle A; Ruhle A; Pich D; Keppler OT; Hammerschmidt W
PLoS Pathog; 2021 Apr; 17(4):e1009117. PubMed ID: 33857265
[TBL] [Abstract][Full Text] [Related]
62. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
Woellmer A; Arteaga-Salas JM; Hammerschmidt W
PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
[TBL] [Abstract][Full Text] [Related]
63. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
64. Epstein-Barr virus (EBV) and lymphomagenesis.
Cesarman E
Front Biosci; 2002 Feb; 7():e58-65. PubMed ID: 11815280
[TBL] [Abstract][Full Text] [Related]
65. The pathogenesis of Epstein-Barr virus persistent infection.
Thorley-Lawson DA; Hawkins JB; Tracy SI; Shapiro M
Curr Opin Virol; 2013 Jun; 3(3):227-32. PubMed ID: 23683686
[TBL] [Abstract][Full Text] [Related]
66. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
67. Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.
Iempridee T; Reusch JA; Riching A; Johannsen EC; Dovat S; Kenney SC; Mertz JE
J Virol; 2014 May; 88(9):4811-27. PubMed ID: 24522918
[TBL] [Abstract][Full Text] [Related]
68. The Epigenetic Life Cycle of Epstein-Barr Virus.
Hammerschmidt W
Curr Top Microbiol Immunol; 2015; 390(Pt 1):103-17. PubMed ID: 26424645
[TBL] [Abstract][Full Text] [Related]
69. Host genetic variants and gene expression patterns associated with Epstein-Barr virus copy number in lymphoblastoid cell lines.
Houldcroft CJ; Petrova V; Liu JZ; Frampton D; Anderson CA; Gall A; Kellam P
PLoS One; 2014; 9(10):e108384. PubMed ID: 25290448
[TBL] [Abstract][Full Text] [Related]
70. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation.
Kaye KM; Izumi KM; Li H; Johannsen E; Davidson D; Longnecker R; Kieff E
J Virol; 1999 Dec; 73(12):10525-30. PubMed ID: 10559372
[TBL] [Abstract][Full Text] [Related]
71. Identification of stathmin 1 expression induced by Epstein-Barr virus in human B lymphocytes.
Baik SY; Yun HS; Lee HJ; Lee MH; Jung SE; Kim JW; Jeon JP; Shin YK; Rhee HS; Kimm KC; Han BG
Cell Prolif; 2007 Apr; 40(2):268-81. PubMed ID: 17472732
[TBL] [Abstract][Full Text] [Related]
72. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
[TBL] [Abstract][Full Text] [Related]
73. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
Shaknovich R; Basso K; Bhagat G; Mansukhani M; Hatzivassiliou G; Murty VV; Buettner M; Niedobitek G; Alobeid B; Cattoretti G
Haematologica; 2006 Oct; 91(10):1313-20. PubMed ID: 17018379
[TBL] [Abstract][Full Text] [Related]
74. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
75. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
76. Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency.
Homa NJ; Salinas R; Forte E; Robinson TJ; Garcia-Blanco MA; Luftig MA
J Virol; 2013 Nov; 87(22):12291-301. PubMed ID: 24027308
[TBL] [Abstract][Full Text] [Related]
77. Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein-Barr virus infection.
SoRelle ED; Dai J; Reinoso-Vizcaino NM; Barry AP; Chan C; Luftig MA
Cell Rep; 2022 Aug; 40(9):111286. PubMed ID: 36044865
[TBL] [Abstract][Full Text] [Related]
78. The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.
Dyson OF; Pagano JS; Whitehurst CB
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724765
[TBL] [Abstract][Full Text] [Related]
79. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
80. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
Rechsteiner MP; Bernasconi M; Berger C; Nadal D
Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
